

## **Aarti Pharmalabs Limited**

## Q1 FY 24 Results Presentation

Ø



AARTI PHARMALABS LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the AARTI PHARMALABS LIMITED.

All information contained in this presentation has been prepared solely by AARTI PHARMALABS LIMITED. AARTI PHARMALABS LIMITED does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.











\_ \_ \_ \_ \_ \_ \_ \_ \_ \_ \_ \_ \_

## **Company Overview**

### Aarti Pharmalabs at a Glance



#### **Overview**


- Established by first generation technocrats in 1984
- Specialized key business verticals

6


- API & Intermediates,
- CDMO & CMO Services
- Xanthine derivatives & allied
- Strong R&D capabilities with IPRs for customized products
- Strategically located: In western India with proximity to ports
- Largest Indian Manufacturer for Xanthine Derivatives (Caffeine and Others)

**Key Metrics** 

#### FY 23-24 Q1 - Consolidated Revenue Breakup (Rs Cr)




#### FY 23-24 Q1 Financial Highlights






### Journey



#### **Manufacturing Facilities**



## **Key Business Verticals**



#### **APIs and Intermediates**

- **US FDA approved manufacturing facility**
- Exports to lucrative regulated markets -US, EU and Japan contributes to 53% of total exports.
- Backward integrated intermediates for most APIs
- Distinct advantage having dedicated USA, Japan and EU approvals
- Dedicated blocks for Anti-Cancer and Cortico Steroids products
- HPAPIs development and manufacturing
- Flow chemistry from lab to manufacturing
- □ Complete CMC documentation support


#### **CDMO / CMO Services**

- CRAMs activity focused on API & intermediates
- Working with 14 Innovators & Big Pharma companies
- Development and manufacturing of RSMs, KSMs for NCEs
- Dedicated R&D & Pilot facilities focusing CDMO.
- 16 Products commercialized and 12 products under development by Innovators.
- **CMO** offerings for regulated markets.

#### Xanthine derivatives & Allied (Caffeine and others)

- Largest Indian Manufacturer for Xanthine Derivatives (Caffeine and others)
- Xanthine derivatives find applications in beverages, nutraceuticals, cosmetics and pharmaceuticals
- Aarti's capabilities 2 dedicated plants
- Key certifications "Star Kosher", "HACCP", "Sedex SMETA-4PillarP", "FSSC-22000 (GFSI)" for manufacturing & testing..





#### **Strong Presence in API & Intermediates**

APIs have been commercialized by APL since it entered the pharma business in year 2000

50



**New APIs** are under development at APL's dedicated R&D facility for pharmaceuticals **US DMF approvals** obtained across multiple therapeutic areas 20 CEP approvals available for sale in European Union across

therapeutic

multiple

areas


## ~100

**Generic Intermediates** are available at R&D, Pilot and Commercial scales


Major therapeutic categories of Generic APIs for regulated markets



Q1 FY24 Export and Domestic Revenue







## CDMO / CMO



- □ Sustainable supply for APIs/NCEs/Intermediates in commercial scale
- Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS)
- EHS and Quality are the highest priority. Facilities were audited as per PSCI principles
- High potent molecules (Oncology/Cytotoxic) development and manufacturing
- □ Backward integration strength for raw materials


#### **CDMO/CMC** Services

- Synthetic Route Scouting & Design
- Process Development (DoE and QbD) & lab demonstration
- Process Engineering (Data Generation)
- Analytical method development and validations
- Custom Synthesis from kg to multi ton scales
- **Kilo & Pilot Scale Manufacturing (non-GMP & GMP) for IND phase and Tox batches**
- Drug substances manufacturing for Clinical supplies (Ph-I/II/III)
- Process Validations
- $\square$  HPAPIs (OEL: 1 10 µg / m<sup>3</sup>; OEB: 4) development and manufacturing
- Impurity Profiling (including impurities & reference standards synthesis)
- CH Stability Studies
- Launch support and commercial manufacturing
- Strong know-how in end-to-end CMC documentation for regulatory filings



#### Manufacturing Capabilities & Strengths





Strong footprints with global Accreditation					
FDA	edom	KPA			
EU		GMP			
<b>150</b> 9001:2015	9001:2008				

Site/Unit Name	Regulatory Agency	Month and Year of Audit
	USFDA	Mar 2008, Sep 2011, Mar 2015, Dec 2016, Feb 2020
Unit IV, Tarapur, Mumbai	EUGMP	Apr 2008, May 2012, Aug 2013, Jan 2015
	EDQM	Sep 2019
	KFDA	Nov 2017
	COFEPRIS	Apr 2017, May 2017
Unit II, CSD, Vapi, Gujarat	USFDA	Sep 2009, Aug 2017
Unit I, Dombivli, Mumbai	USFDA	Jun 2022

### **Xanthine Derivatives**



- Xanthine derivatives are synthetic compounds that resemble natural occurring xanthines such as caffeine etc.,
- Commonly used as mild stimulants & bronchodilators, notably in the treatment of asthma or influenza symptoms
- 2 dedicated manufacturing units
- Aggregate Capacities of about 5000 MTA for Xanthine Derivatives.
- One backward integrated unit for providing KSM for Xanthine derivatives.
- APL has about 15-20% Global Market Share
- Sole Non Chinese integrated manufacturer. Benefitting from China + 1.





3	70+	7	13	52	
State-of-the-art R&D centres at Maharashtra & Gujarat	Scientists	PHDs.	Patents Granted	Process patents filed	
		1	150+	50+	
			Process for more than 150 Intermediates developed and manufactured on kilo lab scale	More than 75 API commercialized	
			160	<b>39 crs</b>	
			Developing 40 products per Year in next four years	R&D Spend in FY23	

## **Strong Focus on R&D & Process Innovation**



#### Innovation at various reactions

- Carbohydrate Chemistry
- Chiral Chemistry
  - Asymmetric Synthesis
  - Bio Catalysts
  - Chiral Epoxides
  - Kinetic Resolution
- Coupling Reactions Chemistry
  - C-C Coupling
  - C-N Coupling
- Isomerization Reactions
- Triphosgene Reactions
- Steroids synthesis
- Flow Reaction with Phase transfer catalyst.

Strong focus on R&D and process innovation

- Aarti has been increasing its presence in the fast growing Pharma segment by going through various inhouse innovations and having its own IP.
- Focus on lifestyle APIs and Intermediates





#### **Environment - Highlights**

- ISO 14001 : 2015 certification
- All plants are Zero Liquid Discharge (ZLD) plants
- Approx. 50% water of total water consumption is recycled
- Green chemistry principles incorporated during product development stage
- Recycle & reuse of solvents and safe disposal of Hazardous waste
- Regulatory compliance monitoring through Compliance Mgt. System (CMS)

### **Social - Highlights**


- Hazard Identification and Risk Assessment (HIRA), Hazardous Area Classification (HAC) and work permit system in place
- Safety Trainings Induction, On the job, Classroom, Demos
- Incident management "Safety Alert", Learning from Incidents, Root cause analysis and Global CAPA Implementation
- Safety Thought For The Day- One slide tool circulated
- Industrial Hygiene study conducted
- Stregthened HR policies and procedures, Incorporating requirements of UN Global Compact, International Labour Organisation's (ILO) Declaration and Sexual Harassment of Women at Workplace Act, 2013, etc
- Variousinitatives to improve diversity and inclusion

#### **Governance - Highlights**


- Robust Compliance Monitoring Framework - implemented PWC's GRC tool to track & regularly monitor various governance aspects
- Internal monitoring and control systems for anti - corruption, bribery and anti - competitive practices
- Core Business Process digitized on a robust SAP ERP backbone
- Environment, Health, Safety & Quality processes digitized on Intelex Cloud platform
- APMS at par with CCPS & OHSAS

## **Financial Performance**











### Q1 FY24 – Consolidated Profit & Loss

Particulars (Rs. Crore)	Q1 FY24	Q4 FY23	Q-o-Q (%)	Q1 FY23	Y-o-Y (%)
Gross Income from Operations	458	485	-5.50%	457	0.21%
Exports	169	204	-17.32%	193	-12.58%
% of Total Income	36.7%	42.0%		42.1%	
EBITDA	85	81	5.73%	85	0.76%
EBITDA Margin (%)	18.6%	16.6%		18.5%	
EBIT	68	65	5.20%	72	-5.74%
EBIT Margin (%)	14.85%	13.33%		15.81%	
PAT	47	43	9.85%	52	-9.15%
PAT Margin (%)	10.26%	8.82%		11.33%	
EPS (Rs.)	5.20	4.73	9.85%	5.72	-9.15%



### Q1 FY24 – Standalone Profit & Loss

Particulars (Rs. Crore)	Q1 FY24	Q4 FY23	Q-o-Q (%)	Q1 FY23	Y-o-Y (%)
Gross Income	363	374	-3.01%	373	-2.72%
Exports	143	162	-11.73%	179	-20.11%
Exports %	39%	43%		48%	
EBITDA	82	77	6.26%	79	3.67%
EBITDA (%)	22.48%	20.52%		21.09%	
EBIT	66	63	5.79%	66	-0.21%
EBIT (%)	18.23%	16.71%		17.77%	
PAT	48	40	19.09%	47	0.80%
PAT (%)	13.12%	10.69%		12.66%	
EPS (Rs.)	5.26	4.41	19.09%	5.21	0.80%

## Q1 FY 24 other highlights




- The Company continues to focus on selling APIs and Intermediate in the Regulated markets. During the last financial year 22-23, the Company commissioned an additional Block in its API manufacturing plant. The validation batch samples for a few key products are awaiting customer approvals.
- The CDMO / CMO pipeline remains strong and would continue to remain a significant growth area.
- On the CDMO / CMO business, strong scale-up & commercial manufacturing expertise of over 2 decades, is helping to enhance customer confidence and hence service needs of Innovators.
- > The Company in Q1 expanded Xanthine Products capacities by debottlenecking.
- ➤ With its strong Chemistry and manufacturing capability, we will continue to look for Backward integration opportunities to become China independent. One of the projects estimated to be completed in Q2 of this year is to manufacture the main RM for Xanthine Products which is currently being imported.
- ➤ The work on the Greenfield Project at Atali, Gujarat has gained momentum in this Quarter. The Company expects to complete the Project in H2 of FY 24-25.


## **Growth Strategies**

#### **Our Growth Strategy**



Increase in capacities of existing products & Adding new 40+ Value added product each year.





#### Atali Project

- ~ 80 acres of land in Gujarat (between Dahej & Bharuch)
- Adding 400+KL reactor volume in Phase1 and target to add similar capacities in future
- Capex of about 350-500 crs in Phase 1
- Construction works initiated.
- Commercialization expected in FY25

Increase presence in regulated market

Outlook









# **THANK YOU**

#### **Aarti Pharmalabs Limited**

#204, Udyog Kshetra, 2<sup>nd</sup> Floor, Mulund Goregaon Link Road,

Mulund West, Mumbai - 400080, Maharashtra, India.

@Email: investorrelations@aartipharmalabs.com

**C**ontact: +91 22 67976666